$IOVA 🗞️Trump Administration Shift Puts This Corner of Biotech Back in Favor.
“With the FDA’s hard-liners gone, investors are rushing back into rare-disease bets.”
The article is mainly about rare disease biotech, but I think the broader point applies to biotech in general: a
